(P-364) Efficacy and Safety by Sex Assigned at Birth After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 48 Results from Two Phase 3 Randomized, Active-Controlled Studies in Adults Living with HIV-1

Professor, Medicine; Chief, Division of Infectious Diseases and Travel Medicine
Georgetown University Medical Center, Washington, DC, USA
Washington, DC, United States

University Health Network
Toronto, Ontario, Canada

Hospital Hernán Henríquez Aravena
Temuco, Araucania, Chile

Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern
Bern, Bern, Switzerland

Farabi Wellness Center
Las Vegas, Nevada, United States

Clinical HIV Research Unit (CHRU), Wits Health Consortium (WHC), Health Science Research Office (HSRO), Faculty of Health Sciences, University of Witwatersrand
Johannesburg, Gauteng, South Africa

Be Part Research (PTY) LTD
Paarl, Western Cape, South Africa

Division of Infectious Diseases, Geneva University Hospital, University of Geneva
Geneva, Geneve, Switzerland

Medical Director
Central Texas Clinical Research, Austin, TX, USA
Austin, Texas, United States

Professor of Infection and Inequities
Queen Mary University of London
london, England, United Kingdom

Merck & Co., Inc.
Rahway, New Jersey, United States

Merck & Co., Inc
Rahway, New Jersey, United States

Merck & Co., Inc.
Rahway, New Jersey, United States

MSD
Puteaux, Haute-Normandie, France

Merck & Co., Inc.
Rahway, New Jersey, United States

Merck & Co., Inc.
Rahway, New Jersey, United States

Director, Clinical Research- Infectious Diseases
Merck & Co., Inc.
Kenilworth, NJ, United States